MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans

Summary: The immunogenicity of HIV DNA and MVA vaccines administered in a DDMM regimen could be improved using the PharmaJet Stratis needle-free injection device and formulation of the DNA vaccines with CpG adjuvant.

Summary: In this study, a serological assay was used to measure antibody responses post-vaccination and compared to immune responses from natural infection. The results showed that vaccination induced a more robust immune reaction and that levels of neutralizing and anti-RBD antibody binding were significantly higher in pre-immune participants compared to immunologically naive participants.

Summary: In May 2022, a novel cluster of monkeypox virus infections in humans was detected, causing global concern. Vaccines based on the vaccinia virus have been highly effective against monkeypox viruses in the past, but the current outbreak involves genetic variations that may impact vaccine-induced immune recognition. However, research suggests that VACV-based vaccines, including MVA-BN and ACAM2000, are still highly cross-reactive against the newly observed monkeypox viruses.

Summary: Neisseria meningitidis is both a normal colonizer of the human nasopharynx and a pathogen causing devastating invasive disease. Immunization is the best tool to protect against meningococcal infections. Recent efforts using humanized mouse models have revealed insights into the impact of different meningococcal vaccines on nasal colonization and immunity, shedding light on key mechanistic aspects for future research.